Skip to content
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • Jylamvo
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Company Updates

photo

University City Science Center Bootcamp, Philadelphia, USA

March 7th 2022February 14th 2020

Read More

Photo

Worldwide Association of MBA’s Best Entrepreneurial Venture Award (Private Sector) 2020

April 15th 2021February 7th 2020

Read More

photo

J.P. Morgan Annual Healthcare Conference, San Francisco, USA

March 7th 2022January 10th 2020

Read More

Photo

Sharon and Orlaith featured in the Irish Times Top 50 people to watch in 2020

April 18th 2021January 4th 2020

Read More

Photo

SodEXo Women Mean Business (WMB) Female Newcomer Award 2019

April 15th 2021October 20th 2019

Read More

Shorla Oncology

SH-111 Successful FDA pre-IND meeting

March 7th 2022October 7th 2019

Read More

Photo

Shorla Oncology featuring in Enterprise Ireland and the Local Enterprise Offices ‘Start’ campaign

March 7th 2022September 24th 2019

Read More

Photo

Ireland’s Best Young Entrepreneur 2019

March 7th 2022September 15th 2019

Read More

Shorla Oncology

SH-105 Successful FDA pre-IND meeting

March 7th 2022June 14th 2019

Read More

Older posts
Newer posts
Page1 … Page9 Page10 Page11 Page12
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP
PRIVACY POLICY
Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • Jylamvo
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.